Ian Clark has served as a member of Guardant Health's Board since January 2017 and is the Company's lead independent director.
Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech, of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations, and before that as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe and France.
Mr. Clark currently serves on the boards of Takeda Pharmaceutical Company Limited, Olema Pharmaceuticals, Inc., Kyverna Therapeutics Inc., Corvus Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. In June 2026, he will end his service on the Board of Takeda and has communicated his intent to further reduce his board service in 2026. He previously served on the boards of Shire Pharmaceuticals, Kite Pharma, Gyroscope, Forty Seven, Agios, Dendreon, Vernalis, AVROBIO, Inc. and GoodRx Holdings, Inc. He is an advisor to KKR and was previously an advisor at Lazard, Blackstone Life Sciences, and Perella Weinberg Partners.
Mr. Clark received a B.Sc. and an honorary doctorate in biological sciences from Southampton University.